Discover March 2025’s top biotech deals, featuring major collaborations in small molecules, bispecific antibodies and protein ...

The U.S. Food and Drug Administration on Friday approved Sanofi SA’s (NASDAQ:SNY) Qfitlia (fitusiran), the first antithrombin ...

HBM Healthcare Investments AG / Key word (s): Annual Results HBM Healthcare Investments expects to report a net profit of CHF 19 million for the 2024/2025 financial year 01-Apr-2025 / 17:49 CET/CEST ...

The European Commission has referred Eisai and Biogen’s application to an appeals committee. Elsewhere, Opthea warned of ...

Sanofi hires former GSK development head Chris Corsico as global R&D head, replacing Dietmar Berger who left for Gilead. Move aligns with €2B R&D investment strategy.

In connection with the start of the phase 3 trials of PCV21, Sanofi has expanded its alliance with South Korea-based SK Bio, first signed more than a decade ago, paying an upfront fee of €50 ...

Sanofi signs $1.9bn deal to buy Dren Bio autoimmune drug UK is becoming an 'outlier' for pharma, hitting investment Sofinnova closes new fund and backs a trio of new biotechs ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...